Recent research published in *Nature* highlights a novel application of the CRISPR enzyme Cas12a2, which can be programmed to destroy DNA in cancer cells expressing specific disease-associated RNA, potentially targeting hard-to-treat mutations like those in the TP53 gene. This approach offers a new avenue for precision therapies that selectively eliminate diseased cells while preserving healthy ones.
The development of the Cas12a2 enzyme, which can be programmed to detect specific mutations in disease-associated RNA and subsequently destroy DNA only in cells expressing that RNA, represents a significant advancement in precision medicine. This approach has the potential to target 'undruggable' mutations, including common cancer-associated defects such as those in the TP53 gene, offering a new class of therapies that selectively eliminate diseased cells while preserving healthy ones. This breakthrough could be particularly impactful for developing treatments for cancers with hard-to-target genetic profiles.